An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B

Inclusion Criteria: * The patient has completed the previous CLDT600A2407 study and is able to immediately enter this extension study with no study drug discontinuation * Patient is willing and able to comply with the study drug regimen and all other study requirements * The patient is willing and able to provide written informed consent to participate in the extension study. Exclusion Criteria: * Patient is pregnant or breastfeeding. * Patient is co-infected with HCV, HDV, or HIV. * History of malignancy of any organ system, treated or untreated, within the past 5 years with the exception of localized basal cell carcinoma of the skin. Other protocol-defined inclusion/exclusion criteria may apply.